Is Sermorelin Legal in South Carolina?

The Federal Legal Framework That Governs Sermorelin Everywhere

Sermorelin's legal status in South Carolina begins at the federal level. Federal law sets the floor; state law can add requirements but cannot override FDA authority over drug manufacturing and interstate pharmacy commerce.

Sermorelin acetate is a synthetic 29-amino-acid analogue of endogenous growth-hormone-releasing hormone (GHRH). An FDA-approved finished product called Geref (sermorelin acetate for injection) was marketed by Serono Laboratories but was voluntarily withdrawn from the U.S. Market in 2008 for commercial, not safety, reasons. FDA drug discontinuation records confirm the withdrawal was not due to a safety or efficacy deficiency.

Why Withdrawal Does Not Mean Illegal

A drug's market withdrawal does not render it a prohibited substance. The FDA's authority to block compounding of a specific active pharmaceutical ingredient (API) comes from two specific mechanisms: (1) placing it on the "difficult to compound" or Category 2 bulk substances list under Section 503A of the Federal Food, Drug, and Cosmetic Act, or (2) listing it on the 503B prohibited/withdrawn list. As of the date of this article's last review, sermorelin does not appear on either list. The FDA publishes and maintains the current 503A bulk substances list at its official guidance portal.

The 503A vs. 503B Distinction

The two compounding pathways matter significantly for South Carolina patients and clinics.

503A pharmacies are traditional compounding pharmacies that prepare drug products for individual patient prescriptions. They must be licensed in the state where the patient resides (South Carolina, in this case) and must comply with applicable USP standards, including USP <797> for sterile preparations. Sermorelin injections require sterile compounding. A 503A pharmacy can legally prepare sermorelin for a specific patient if a licensed prescriber has issued a valid, patient-specific prescription. The FDA's overview of the 503A framework details these requirements.

503B outsourcing facilities are registered with the FDA and may produce larger batches for office stock without patient-specific prescriptions. They must follow current Good Manufacturing Practice (cGMP) standards. A South Carolina clinic or practice may order sermorelin from a registered 503B facility for on-site administration. The same federal prohibited-substance rules apply. FDA maintains a public registry of all 503B outsourcing facilities.

South Carolina State Law: What the State Adds

South Carolina does not have a state-specific statute that independently bans, restricts, or schedules sermorelin beyond federal requirements. That is a factual statement, not legal advice. The relevant state legal architecture has three pillars.

The South Carolina Controlled Substances Act

Sermorelin is not listed as a controlled substance under the South Carolina Controlled Substances Act, codified at S.C. Code Ann. § 44-53-110 through § 44-53-590. The state schedules (Schedules I through V) mirror the federal DEA schedules with some additions, but GHRH analogues are absent from both the state and federal controlled substance schedules. The DEA's current list of controlled substances is maintained by the U.S. Drug Enforcement Administration.

This means a DEA controlled-substance registration is not required to prescribe or dispense sermorelin, and patients do not face the additional pharmacy monitoring requirements (such as mandatory prescription drug monitoring program (PDMP) checks) that apply to Schedule II-IV drugs.

The South Carolina Board of Pharmacy

The South Carolina Board of Pharmacy regulates pharmacy practice in the state under S.C. Code Ann. § 40-43. Any pharmacy compounding and dispensing sermorelin to a South Carolina patient must hold an active South Carolina pharmacy license. Out-of-state 503A pharmacies shipping into South Carolina must obtain a non-resident pharmacy permit from the Board. The South Carolina Board of Pharmacy maintains licensure requirements and permit information through the Department of Labor, Licensing and Regulation.

Sterile compounding of sermorelin injections must comply with USP <797> standards for cleanroom classification, beyond-use dating, and sterility testing. A pharmacy that cannot demonstrate USP <797> compliance is operating outside of accepted standards regardless of whether sermorelin itself is legal.

The South Carolina Medical Practice Act and Prescriber Authority

Any licensed South Carolina physician (MD or DO), nurse practitioner with prescriptive authority, or physician assistant acting under a supervising agreement may prescribe sermorelin for a legitimate medical purpose. The South Carolina Medical Practice Act (S.C. Code Ann. § 40-47) requires prescriptions to be issued in the context of a valid patient-provider relationship. The South Carolina Board of Medical Examiners oversees physician licensing and medical practice standards.

Telehealth prescribing is explicitly permitted in South Carolina. The state enacted the Telehealth Alliance of South Carolina Act and the South Carolina Telehealth Medicaid parity law. A prescription for sermorelin issued after a synchronous video consultation with a licensed South Carolina prescriber satisfies the patient-provider relationship requirement.

Who Qualifies for a Sermorelin Prescription in South Carolina?

Sermorelin is not a medication that any patient can simply request and receive. A clinically appropriate evaluation is required before a prescription is appropriate. While there are no statutory criteria for sermorelin specifically (it is not a controlled substance with mandatory diagnosis codes), standard of care establishes evidence-based thresholds.

Clinical Indications Commonly Used

The original FDA-approved indication for Geref was diagnosis of growth-hormone deficiency in children. In adult practice, compounded sermorelin has been used off-label to stimulate endogenous GH pulsatility in adults with documented or clinically suspected growth-hormone insufficiency, age-related GH decline, or recovery support after pituitary dysfunction.

A 2006 study by Sigalos and Pastuszak published in Sexual Medicine Reviews reviewed GHRH secretagogues and noted that sermorelin stimulates GH release through the pituitary's natural feedback arc, preserving hypothalamic-pituitary-axis (HPA) regulation more than exogenous recombinant human growth hormone (rhGH). This physiological mechanism is one reason prescribers prefer it in certain populations. The full text is indexed in PubMed.

Peer-reviewed evidence also documents sermorelin's effect on body composition. A randomized controlled trial by Walker et al. (1990) found that sermorelin administration increased growth hormone secretion and lean body mass in GH-deficient adults, with a response rate that differed meaningfully from placebo. This foundational trial is available through the National Library of Medicine.

Typical Pre-Prescription Workup

Most reputable prescribers in South Carolina will order baseline labs before writing a sermorelin prescription. Those typically include:

• Serum IGF-1 (insulin-like growth factor 1), the primary surrogate marker for GH axis activity
• Fasting insulin and glucose to assess metabolic context
• A comprehensive metabolic panel (CMP)
• Thyroid panel (TSH, free T4), because hypothyroidism blunts GH response
• Sex hormone panel (testosterone, estradiol, LH, FSH) to rule out co-existing deficiencies

IGF-1 is the most clinically actionable single marker. The Endocrine Society's 2011 Clinical Practice Guideline on Growth Hormone Deficiency in Adults specifies that a low serum IGF-1 in the appropriate clinical context supports further GH axis evaluation. The guideline is published in the Journal of Clinical Endocrinology and Metabolism, indexed through the Endocrine Society.

A normal IGF-1 does not automatically exclude sermorelin use in all clinical contexts, but it shifts the risk-benefit calculus. The prescriber's documented clinical reasoning is the legal and ethical anchor.

How to Get Sermorelin in South Carolina: A Step-by-Step Path

Getting sermorelin legally in South Carolina involves four sequential steps. Shortcuts that skip any of these steps expose the patient (and provider) to legal and safety risk.

Step 1: Identify a Licensed South Carolina Prescriber

The prescriber must hold an active South Carolina license from the Board of Medical Examiners (for MDs and DOs) or the Board of Nursing (for NPs) or the Board of Medical Examiners under a physician supervision agreement (for PAs). Telehealth providers licensed in South Carolina satisfy this requirement.

Be cautious of websites that offer sermorelin without a consultation or that claim a "prescription is not needed." Sermorelin is a prescription drug under federal law (21 U.S.C. § 353(b)) regardless of its non-controlled status. Dispensing it without a valid prescription is a federal pharmacy violation.

Step 2: Complete a Clinical Evaluation

The consultation, whether in-person or via telehealth, must establish a genuine patient-provider relationship. The prescriber reviews history, symptoms, and labs, then makes an independent clinical determination. A prescription issued without this evaluation may be considered invalid by both state and federal authorities.

Step 3: Verify the Compounding Pharmacy

Ask the pharmacy for:

• Its South Carolina Board of Pharmacy license number (or non-resident permit number)
• Its USP <797> compliance documentation or most recent sterility testing records
• The Certificate of Analysis (CoA) from the API supplier confirming peptide identity and purity

A compliant pharmacy will provide all three without hesitation. One that deflects these requests should not be used.

Step 4: Follow the Prescribed Protocol

Most sermorelin protocols involve subcutaneous self-injection, typically 200-500 mcg administered before bedtime to align with the natural nocturnal GH pulse. Dosing is titrated over 3-6 months based on symptomatic response and follow-up IGF-1 testing. The prescriber should establish specific re-evaluation timepoints.

Risks, Contraindications, and What South Carolina Law Requires Prescribers to Document

Sermorelin's safety profile is generally favorable compared to exogenous rhGH. The most common adverse effects include injection-site reactions, transient facial flushing, and headache. Because it stimulates the pituitary rather than bypassing it, the risk of GH excess (acromegaly) is lower, though not zero at supraphysiologic doses.

Two absolute contraindications require documentation in the medical record:

1. Active malignancy. Growth factors can theoretically stimulate tumor growth. The American Cancer Society's position on GH secretagogues in cancer patients warrants individual risk-benefit analysis. Oncologic safety considerations for GH axis stimulation are discussed in the NCI's published literature.

2. Hypothyroidism, untreated. An under-active thyroid blunts GH response. The Endocrine Society guideline recommends correcting thyroid status before initiating GH axis therapy. See the Endocrine Society's GH deficiency guideline.

South Carolina's Medical Practice Act requires that prescribers maintain adequate medical records (S.C. Code Ann. § 40-47-37), which includes the clinical rationale for any off-label prescription. A chart note documenting symptom burden, lab results, informed consent discussion, and the prescriber's reasoning is both a legal requirement and a professional standard.

What Is Not Legal: Common Compliance Failures to Avoid

Understanding what is permitted also means understanding what falls outside legal boundaries.

Buying sermorelin without a prescription from a research-chemical vendor is not legal for human use. Research-chemical suppliers frequently label peptides "for research use only, not for human consumption" to sidestep FDA scrutiny. That label does not change the legal status of self-administration. The FDA has issued warning letters to multiple peptide vendors, and the agency has stated that selling these substances for human use without a prescription violates the FDCA. The FDA's warning letters to peptide companies are publicly searchable.

Importing sermorelin from foreign pharmacies without FDA authorization is also not legal for individual patients. Section 503 personal import exemptions do not apply to injectable prescription drugs.

Compounding outside of USP <797> is a compliance failure. A sterile injectable peptide compounded in a non-sterile environment represents an adulterated drug under federal law, exposing both the pharmacy and the prescriber to liability.

Sermorelin vs. Other GH Secretagogues: Legal Distinctions in 2025

South Carolina patients sometimes ask how sermorelin compares legally to related peptides like ipamorelin, CJC-1295, or tesamorelin. The legal distinctions are real and matter.

Ipamorelin and CJC-1295 are not on the FDA's 503A bulk substances approved list. The FDA's 2023 and 2024 guidance actions placed several peptides, including BPC-157, TB-500, and certain GHRP-class compounds, under increased scrutiny or on prohibited lists for 503B facilities. Ipamorelin and CJC-1295 occupy a legal gray zone: not explicitly banned in 503A compounding as of this writing, but also not on the FDA's positively affirmed list, meaning 503A pharmacies compound them at regulatory risk. Patients and providers should confirm current FDA guidance before using these alternatives. The FDA's current Category 1 and Category 2 503A bulk substance lists are the definitive reference.

Tesamorelin (Egrifta) is an FDA-approved GHRH analogue with a specific indication (HIV-associated lipodystrophy). It is a Schedule-uncontrolled prescription drug available commercially, not through compounding. Off-label prescribing of FDA-approved drugs is legal; compounding a copy of an FDA-approved drug is generally prohibited under 503A rules.

Sermorelin's position is cleaner: it has a history of FDA approval, a documented safety record, and is not on a prohibited compounding list, giving 503A pharmacies a more defensible basis for preparation.

Telehealth and Sermorelin Access in South Carolina

South Carolina permits synchronous telehealth consultations as the basis for prescribing sermorelin. The state's telehealth statute (S.C. Code Ann. § 44-7-3110 et seq.) establishes that a valid patient-provider relationship can be formed via video. A provider licensed in South Carolina who reviews your history, examines labs, discusses treatment options, and issues a prescription via a secure video visit meets the legal standard.

A 2021 systematic review in the Journal of Telemedicine and Telecare found that endocrine and hormone-related telehealth consultations produced equivalent prescription accuracy and patient satisfaction compared to in-person visits, across 14 included studies. That review is indexed at PubMed.

The practical implication: a patient anywhere in South Carolina, including rural counties with limited specialist access, can access a licensed prescriber via telehealth, receive an evidence-based evaluation, and have a sermorelin prescription sent to a compliant compounding pharmacy, all without leaving home.